The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy is available.
R. E. Martell
No relevant relationships to disclose
E. G. Chiorean
No relevant relationships to disclose
H. Youssoufian
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
M. D. Rutstein
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
B. Pytowski
Employment or Leadership Position - ImClone Systems
L. Benjamin
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
L. Abad
Employment or Leadership Position - ImClone Systems
J. Patel
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
T. Steele
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
M. Dowd
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
A. Qin
Employment or Leadership Position - ImClone Systems
C. F. Kukel
Employment or Leadership Position - ImClone Systems
F. E. Fox
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
A. Dontabhaktuni
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
A. Morozov
Employment or Leadership Position - ImClone Systems